Actuate Therapeutics Announces Phase 2 Elraglusib Data for Metastatic Pancreatic Cancer Selected for ASCO GI 2026 Presentation

Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer

Actuate Therapeutics Signs $100M Sales Agreement

BRIEF-Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing

Actuate Therapeutics Inc - Enters at the Market Issuance Sales Agreement With B. Riley and Craig-Hallum - SEC Filing

Actuate Therapeutics Inc - May Sell Common Stock up to $100 Mln - SEC Filing

Actuate Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Craig-Hallum Reaffirms Their Buy Rating on Actuate Therapeutics, Inc. (ACTU)

Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate

Actuate Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Actuate Therapeutics - Data to Support FDA and Ema Submissions Beginning Later This Year, Continuing Into Early 2026

Actuate Therapeutics Inc - Recent Financing Extends Runway Through Key Regulatory Points

Actuate Therapeutics Inc: Amended Elraglusib Ind Application With Updated Clinical Data From Phase 2 Trial for Metastatic Pancreatic Cancer

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

Actuate Therapeutics Shares Drop After Public Offering Prices

BRIEF-Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

Actuate Therapeutics Plans Public Offering of Common Shares

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

BRIEF-Actuate Therapeutics Inc Files For Mixed Shelf Offering Of Up To $250 Million- SEC Filing